STI-103 is under clinical development by Sentynl Therapeutics and currently in Phase I for Muscle Spasticity. According to GlobalData, Phase I drugs for Muscle Spasticity have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STI-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STI-103 overview

STI-103 is under development for the treatment of spasticity.

Sentynl Therapeutics overview

Sentynl Therapeutics is a subsidiary of Zydus Lifesciences Ltd, which provides novel biopharmaceutical medicines. The company is engaged in the development and commercialization of prescription products for rare diseases. Its rare diseases portfolio includes ORGN001 (fosdenopterin) and CUTX-101 (Copper Histidinate). Sentynl Therapeutics is headquartered in California, the US.

For a complete picture of STI-103’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.